134 related articles for article (PubMed ID: 22258923)
1. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.
Reddy VM; Dubuisson T; Einck L; Wallis RS; Jakubiec W; Ladukto L; Campbell S; Nacy CA
J Antimicrob Chemother; 2012 May; 67(5):1163-6. PubMed ID: 22258923
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA
J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637
[TBL] [Abstract][Full Text] [Related]
3. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Wallis RS; Jakubiec W; Mitton-Fry M; Ladutko L; Campbell S; Paige D; Silvia A; Miller PF
PLoS One; 2012; 7(1):e30479. PubMed ID: 22279595
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.
Onajole OK; Govender P; van Helden PD; Kruger HG; Maguire GE; Wiid I; Govender T
Eur J Med Chem; 2010 May; 45(5):2075-9. PubMed ID: 20149497
[TBL] [Abstract][Full Text] [Related]
5. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
Reddy VM; Einck L; Andries K; Nacy CA
Antimicrob Agents Chemother; 2010 Jul; 54(7):2840-6. PubMed ID: 20385864
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.
Jia L; Coward L; Gorman GS; Noker PE; Tomaszewski JE
J Pharmacol Exp Ther; 2005 Nov; 315(2):905-11. PubMed ID: 16085758
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.
Protopopova M; Hanrahan C; Nikonenko B; Samala R; Chen P; Gearhart J; Einck L; Nacy CA
J Antimicrob Chemother; 2005 Nov; 56(5):968-74. PubMed ID: 16172107
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
Wallis RS; Jakubiec WM; Kumar V; Silvia AM; Paige D; Dimitrova D; Li X; Ladutko L; Campbell S; Friedland G; Mitton-Fry M; Miller PF
J Infect Dis; 2010 Sep; 202(5):745-51. PubMed ID: 20629533
[TBL] [Abstract][Full Text] [Related]
10. Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
Bukhdruker S; Varaksa T; Grabovec I; Marin E; Shabunya P; Kadukova M; Grudinin S; Kavaleuski A; Gusach A; Gilep A; Borshchevskiy V; Strushkevich N
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081390
[TBL] [Abstract][Full Text] [Related]
11. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages.
Sood R; Rao M; Singhal S; Rattan A
Int J Antimicrob Agents; 2005 Jun; 25(6):464-8. PubMed ID: 15885988
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
Jia L; Tomaszewski JE; Hanrahan C; Coward L; Noker P; Gorman G; Nikonenko B; Protopopova M
Br J Pharmacol; 2005 Jan; 144(1):80-7. PubMed ID: 15644871
[TBL] [Abstract][Full Text] [Related]
13. Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.
de Knegt GJ; van der Meijden A; de Vogel CP; Aarnoutse RE; de Steenwinkel JE
Int J Antimicrob Agents; 2017 Mar; 49(3):302-307. PubMed ID: 28162983
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.
Sacksteder KA; Protopopova M; Barry CE; Andries K; Nacy CA
Future Microbiol; 2012 Jul; 7(7):823-37. PubMed ID: 22827305
[TBL] [Abstract][Full Text] [Related]
15. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI
Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828
[TBL] [Abstract][Full Text] [Related]
16. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
Williams KN; Brickner SJ; Stover CK; Zhu T; Ogden A; Tasneen R; Tyagi S; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Aug; 180(4):371-6. PubMed ID: 19520903
[TBL] [Abstract][Full Text] [Related]
17. SQ109.
Tuberculosis (Edinb); 2008 Mar; 88(2):159-61. PubMed ID: 18486060
[No Abstract] [Full Text] [Related]
18. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.
Zhu T; Friedrich SO; Diacon A; Wallis RS
Antimicrob Agents Chemother; 2014 Jun; 58(6):3306-11. PubMed ID: 24687496
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Yip PC; Kam KM; Lam ET; Chan RC; Yew WW
Int J Antimicrob Agents; 2013 Jul; 42(1):96-7. PubMed ID: 23684005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
